Coexistence of Epidermal Growth Factor Receptor 19 Deletion and 21 Point Mutation in Nonsmall Cell Lung Cancer: A Report of 3 Cases
Abstract
The coexistence of an epidermal growth factor receptor (EGFR) 19 deletion and 21 point mutation represents a rare event in patients with nonsmall cell lung cancer. We present three cases of female patients with lung adenocarcinoma who had the double genetic mutations. The patients were all treated with EGFR tyrosine kinase inhibitors (TKIs) because the tumors were judged inoperable. In all cases, tumor progression occurred after a few months. Further studies are needed to determine whether the EGFR‑TKI resistance time in patients with double genetic mutations is longer than that in patients with a single mutation.